RT Journal Article
T1 Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver.
A1 López-Bermudo, Lucía
A1 Luque-Sierra, Amparo
A1 Maya-Miles, Douglas
A1 Gallego-Durán, Rocío
A1 Ampuero, Javier
A1 Romero-Gómez, Manuel
A1 Berná, Genoveva
A1 Martín, Franz
K1 crosstalk
K1 extracellular vesicles (EVs)
K1 hepatokines
K1 liver
K1 nonalcoholic fatty liver disease
K1 pancreatic islets
K1 type 2 diabetes
K1 β-cell
AB Tissue-to-tissue crosstalk regulates organ function, according to growing data. This phenomenon is relevant for pancreatic β-cells and the liver, as both tissues are involved in glucose homeostasis and lipid metabolism. The ability to fine-tune regulation and adaptive responses is enabled through communication between pancreatic β-cells and the liver. However, the crosstalk between both tissues changes when metabolic dysregulation is present. Factors and cargo from extracellular vesicles (EVs) released by liver and pancreatic β-cells that reach the circulation form the words of this interaction. The molecules released by the liver are called hepatokines and are usually secreted in response to the metabolic state. When hepatokines reach the pancreatic islets several mechanisms are initiated for their protection or damage. In the case of the crosstalk between pancreatic β-cells and the liver, only one factor has been found to date. This protein, pancreatic derived factor (PANDER) has been proposed as a novel linker between insulin resistance (IR) and type 2 diabetes mellitus (T2D) and could be considered a biomarker for non-alcoholic fatty liver disease (NAFLD) and T2D. Furthermore, the cargo released by EVs, mainly miRNAs, plays a significant role in this crosstalk. A better knowledge of the crosstalk between liver and pancreatic β-cells is essential to understand both diseases and it could lead to better prevention and new therapeutic options.
SN 1664-2392
YR 2022
FD 2022-05-16
LK http://hdl.handle.net/10668/20566
UL http://hdl.handle.net/10668/20566
LA en
DS RISalud
RD Apr 9, 2025